GlaxoSmithKline Announces Regulatory Submission To FDA For Albiglutide

GSK Reports Regulatory Submission For Umeclidinium Monotherapy In U.S.

GlaxoSmithKline Q1 Profit Declines, Backs Full Year Goals

GlaxoSmithKline Q1 Profit Slides - Quick Facts

GSK, Theravance Submits Regulatory Application For UMEC/VI In Japan

Trade GSK now with

1/14/2013 5:47 AM ET

GlaxoSmithKline plc (GSK: Quote,GSK.L) announced a regulatory submission to the US FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. GlaxoSmithKline intends to submit a regulatory application in the European Union in early 2013.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.

Click here to receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

<<Previous 69 Articles

Editors Pick

Stocks Moving Modestly Higher In Early Trading - U.S. Commentary

Stocks have moved modestly higher in early trading on Wednesday, adding to the slim gains posted in the previous session. The major averages have all climbed into positive territory, although buying interest has remained relatively subdued. The major averages have seen some further upside in recent trading, reaching new highs for the young session.

IMF Sees Myanmar Growth At 6.7% This Fiscal

Myanmar's growth is set to accelerate slightly to 6.75 percent in the fiscal year ending March 2014 led by gas production and investment, the International Monetary Fund said on Wednesday. In an Article IV Consultation report, the IMF said Myanmar's economy grew nearly 6.5 percent in the fiscal year...

Bank Of England Split On QE; King's Stimulus Call Defeated For Fourth Month

Bank of England Chief Mervyn King maintained his call for more stimulus for the fourth month and was defeated again by a majority of six members as in previous months who cited faster-than-expected growth and pipeline impact from previous stimulus. At his penultimate meeting, King along with Paul Fisher and David Miles sought an increase in quantitative easing by GBP 25 billion.